Evonik wins two CPHI China 2026 Pharma Excipients Awards
- Evonik won Market Impact for EUDRAGIT® functional film coating polymers and Advanced Technology for EUDRACAP® colon at CPHI China 2026.
- EUDRAGIT® is used in more than 80 countries and cited in over 23,000 patents; it was introduced to China in the 1990s.
- EUDRACAP® colon is the first ready-to-fill functional capsule targeting the ileo-colonic region and accepts powders, pellets and granules.
- EUDRACAP® colon previously received international recognition at the CPHI Pharma Awards in Frankfurt in 2025.
Awards and recognition
Evonik received two Pharma Excipients Awards at CPHI China 2026 in Shanghai, winning Market Impact for EUDRAGIT® functional film coating polymers and Advanced Technology for EUDRACAP® colon-targeting functional capsules.
EUDRAGIT® market role
EUDRAGIT® is presented as an industry standard for oral controlled drug delivery, used in more than 80 countries and cited in over 23,000 patents. Introduced to China in the 1990s, it has supported the advancement of solid oral dosage technologies and the shift of local manufacturers from high-quality generics to innovative, proprietary drug-delivery solutions.
EUDRACAP® colon technology
EUDRACAP® colon is described as the first ready-to-fill functional capsule on the market to target the ileo-colonic region. It enables oral delivery of sensitive APIs, is compatible with powders, pellets and granules, can be processed using standard capsule-filling equipment, and aims to accelerate development timelines.
Industry context
The Pharma Excipients Awards recognise excipient technologies that elevate industry standards and promote high-quality pharmaceutical development; EUDRACAP® colon also gained acclaim at the CPHI Pharma Awards in Frankfurt in 2025. Evonik said it will strengthen collaboration with customers in China to accelerate differentiated drug development and deliver greater benefits to patients.
Source: Evonik
